CD44 and prostate carcinoma: Targeting CD44 and the Hippo-YAP pathway might be a potential treatment for docetaxel-resistant prostate adenocarcinoma, as docetaxel is a common drug used for metastatic prostatic carcinoma, migration, and invasion of docetaxel-resistant prostate carcinoma cells is promoted by CD44 via induction of Hippo-Yap signaling [20].